associated with reduced survival without neonatal morbidity (0.65 (0.54-0.77), p < 0.0001) and survival without neurodevelopmental impairment at 2 years (0.70(0.57-0.85), p < 0.001). After correction for gestational age and birth weight z-score, no significant association between any measure of neonatal glycaemia and neonatal or 2 year outcomes remained.
associated with reduced survival without neonatal morbidity (0.65 (0.54-0.77), p < 0.0001) and survival without neurodevelopmental impairment at 2 years (0.70(0.57-0.85), p < 0.001). After correction for gestational age and birth weight z-score, no significant association between any measure of neonatal glycaemia and neonatal or 2 year outcomes remained.
Conclusions Method: Children randomised as neonates to a trial of tight vs. standard glycaemic control were assessed at 7 years' corrected age, including Wechsler Intelligence Scale for Children (4 th Ed), Movement Assessment Battery for Children-2, visual acuity, neurological examination, dual x-ray absorptiometry and growth measures. The primary outcome was survival without neurodevelopmental impairment at age 7. Outcomes were compared using linear regression, adjusted for sex, small for gestational age, birth plurality, and the clustering of twins. Body composition measures were also adjusted for height. Data are number (%) or mean AE SD.
Results: Of 88 infants randomised, 20 (23%) were not assessed at 7 years; thus, the primary outcome was available in 68 (77%) children, including 11 (13%) who had died. Survival without neurodevelopmental impairment occurred in 25 / 68 (37%), with no difference between tight (14/35 (40%)) and standard (11/33 (33%)) glycaemic control groups (p = 0.6). Children in the tight group were shorter than those in the standard group (121.3 AE 6.3 vs. 125.1 AE 5.4 cm, p < 0.05), but similar in weight and head circumference. Children in the tight group had more height-adjusted lean mass (18.7 AE 0.3 vs. 17.6 AE 0.2 kg, p < 0.01), but similar fat mass and bone mineral density.
Conclusions: Tight glycaemic control for neonatal hyperglycaemia does not change survival without neurodevelopmental impairment, but does result in reduced height and greater height-adjusted lean mass at school age. Background: Management of infants at risk of Neonatal Abstinence Syndrome (NAS) varies between centres, particularly in relation to in-hospital management. Our practice includes using higher treatment thresholds, observation on postnatal wards, minimisation of NICU admission and early discharge with regular outpatient follow-up.
MANAGEMENT OF INFANTS WITH NEONATAL
Methods: We retrospectively reviewed the records of all inborn infants with a history of maternal perinatal opiate exposure presenting to our perinatal service between the years of 2009 and 2014.
Results: 147 infants at risk of NAS were identified. All infants were seen on outpatient follow-up for a median duration of 9 months (iqr 6-12). 55% (n = 81) were diagnosed with NAS using the modified Finnegan's Scale at a median postnatal age of 2 days. The table below displays the salient features of these infants. All infants requiring treatment with morphine were discharged on oral medication. Morphine was weaned on an outpatient basis with median length of treatment being 42 days (iqr 33-54). Importantly, none of the infants in the study required adjunct pharmacological treatment or readmission for NAS related health concerns.
Infants with NAS = 81

NICU admission for NAS [Percentage (number)]
21% ( Murdoch Childrens Research Institute Background: Children born very preterm (VPT; <32 weeks' gestation) have increased risk for developmental impairments, and their mothers have higher rates of depression and anxiety symptoms across the early years. The aim of the study was to examine whether maternal depression and anxiety symptoms over the first 2 years of life was associated with development in VPT children.
Method: Participants were 149 children born <30 weeks' gestation and their mothers. Maternal depression and anxiety symptoms were assessed at birth, 12, and 24 months', and children's cognitive, language, and social-emotional development was assessed at 24 months corrected age.
Results: Maternal depression or anxiety at birth, 12 or 24 months' corrected age was not associated with cognitive or language development at 24 months. Increased symptoms of depression or anxiety at 12 or 24 months were strongly
